References
- Msaouel P, Lee J, Thall PF. Making patient-specific treatment decisions using prognostic variables and utilities of clinical outcomes. Cancers. 2021;13(11):2741. doi:https://doi.org/10.3390/cancers13112741.
- Lyman GH, Kuderer NM. Randomized controlled trials versus real-world data in the COVID-19 era: a false narrative. Cancer Invest. 2020;38(10):537–42. doi:https://doi.org/10.1080/07357907.2020.1841922.
- Pearl J. Causality: models, reasoning, and inference. Second Edition. Cambridge, U.K.; New York: Cambridge University Press; 2009.
- Shapiro DD, Msaouel P. Causal diagram techniques for urologic oncology research. Clin Genitourin Cancer. 2021;19(3):271.e1–e7. doi:https://doi.org/10.1016/j.clgc.2020.08.003.
- McLoughlin EM, Gentzler RD. Epidermal growth factor receptor mutations. Thorac Surg Clin. 2020;30(2):127–36. doi:https://doi.org/10.1016/j.thorsurg.2020.01.008.
- Senn S. Seven myths of randomisation in clinical trials. Stat Med. 2013;32(9):1439–50. doi:https://doi.org/10.1002/sim.5713.
- MacKinnon DP, Pirlott AG. Statistical approaches for enhancing causal interpretation of the M to Y relation in mediation analysis. Pers Soc Psychol Rev. 2015;19(1):30–43. doi:https://doi.org/10.1177/1088868314542878.
- Rothman KJ, Gallacher JE, Hatch EE. Why representativeness should be avoided. Int J Epidemiol. 2013;42(4):1012–4. doi:https://doi.org/10.1093/ije/dys223.
- Elwood JM. Commentary: on representativeness. Int J Epidemiol. 2013;42(4):1014–5. doi:https://doi.org/10.1093/ije/dyt101.
- Richiardi L, Pizzi C, Pearce N. Commentary: representativeness is usually not necessary and often should be avoided. Int J Epidemiol. 2013;42(4):1018–22. doi:https://doi.org/10.1093/ije/dyt103.
- Richiardi L, Bellocco R, Zugna D. Mediation analysis in epidemiology: methods, interpretation and bias. Int J Epidemiol. 2013;42(5):1511–9. doi:https://doi.org/10.1093/ije/dyt127.
- Cinelli C, Forney A, Pearl J. A crash course in good and bad controls. Available from: SSRN:https://ssrncom/abstract=3689437 or http://dxdoiorg/102139/ssrn3689437. 2020.
- Pearl J. Linear models: a useful “microscope” for causal analysis. J Causal Infer. 2013;1(1):155–70. doi:https://doi.org/10.1515/jci-2013-0003.
- Schmotzer GL. Barriers and facilitators to participation of minorities in clinical trials. Ethn Dis. 2012;22(2):226–30.
- Wallington SF, Dash C, Sheppard VB, Goode TD, Oppong BA, Dodson EE, et al. Enrolling minority and underserved populations in cancer clinical research. Am J Prev Med. 2016;50(1):111–7. doi:https://doi.org/10.1016/j.amepre.2015.07.036.
- Gelman A, Hill J, Vehtari A. Regression and other stories. Cambridge, UK: Cambridge University Press; 2020.
- Senn S. Statistical issues in drug development. 3rd ed. Chichester, England; Hoboken, NJ: John Wiley & Sons; 2021.
- Madhusoodanan J. A troubled calculus. Science. 2021;373(6553):380–3. doi:https://doi.org/10.1126/science.373.6553.380.
- Paragg J. Studying “mixed race”: reflections on methodological practice. Int J Qual Methods. 2014;13(1):347–61. doi:https://doi.org/10.1177/160940691401300117.
- Bareinboim E, Pearl J. Causal inference and the data-fusion problem. Proc Natl Acad Sci USA. 2016;113(27):7345–52. doi:https://doi.org/10.1073/pnas.1510507113.
- Breskin A, Cole SR, Edwards JK, Brookmeyer R, Eron JJ, Adimora AA, et al. Fusion designs and estimators for treatment effects. Stat Med. 2021;40(13):3124–37. doi:https://doi.org/10.1002/sim.8963.
- Dahabreh IJ, Robertson SE, Tchetgen EJ, Stuart EA, Hernán MA. Generalizing causal inferences from individuals in randomized trials to all trial-eligible individuals. Biometrics. 2019;75(2):685–94. doi:https://doi.org/10.1111/biom.13009.
- Bareinboim E, Pearl J. A general algorithm for deciding transportability of experimental results. J Causal Infer. 2013;1(1):107–34. doi:https://doi.org/10.1515/jci-2012-0004.
- Liu K, Meng X-L. There is individualized treatment. why not individualized inference? Annu Rev Stat Appl. 2016;3(1):79–111. doi:https://doi.org/10.1146/annurev-statistics-010814-020310.
- Kent DM, Paulus JK, van Klaveren D, D'Agostino R, Goodman S, Hayward R, et al. The predictive approaches to treatment effect heterogeneity (PATH) statement. Ann Intern Med. 2020;172(1):35–45. doi:https://doi.org/10.7326/M18-3667.